Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: 2 Turkish hospital experience
- Cil, I
- EKENEL, Meltem
- Zirtiloglu, A.
- Karabulut, S.
- Tural, D.
- Aydin, E.
Publication date
January 2020
DOI Publisher
Elsevier BV Journal
Actas Urológicas EspañolasAbstract
Introduction: Sunitinib (SUN) and pazopanib (PAZ) are 2 oral tyrosine kinase inhibitors against vascular endothelial growth factor. Their efficacy and safety in metastatic renal cell carcinoma has been proven with phase iii studies. However, real world data is limited. The objective of this study is to assess the clinical benefit of SUN and PAZ in routine practice
Add to ORKG